AI Article Synopsis
- - The study showcases the largest collection of structured histopathology reports related to chronic rhinosinusitis caused by primary ciliary dyskinesia (PCD-CRS).
- - Although there were some endoscopic differences, the histopathology reports of PCD-CRS were similar to those of cystic fibrosis-related chronic rhinosinusitis (CF-CRS).
- - Patients with PCD-CRS exhibited a higher neutrophil count compared to both healthy individuals and those with idiopathic chronic rhinosinusitis who did not have nasal polyps.
Article Abstract
We present the largest cohort of structured histopathology reports on primary ciliary dyskinesia-related chronic rhinosinusitis (PCD-CRS). Despite endoscopic differences, PCD-CRS and cystic fibrosis-related chronic rhinosinusitis (CF-CRS) had similar structured histopathology reports. Compared to healthy patients and those with idiopathic chronic rhinosinusitis without nasal polyps, patients with PCD-CRS had an increased neutrophil count.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/alr.23303 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immediate Full-Arch Restorations Supported by Conventional Implants Plus Uni- or Bilateral Zygomatic Implants: A Three to Five Years Retrospective Radiologic and Clinical Comparison.
Int J Periodontics Restorative Dent
January 2025
Purpose: The study aimed to compare the short-term outcomes (3.7±0.4yrs) of full-arch immediately loaded fixed maxillary prostheses supported by conventional and unilateral single zygomatic implants versus those supported by conventional and bilateral single zygomatic implants.
View Article and Find Full Text PDFIncreased Incidence of Surgical Intervention for Otitis Media With Effusion Among Patients With Type 2 Inflammatory Diseases.
J Allergy Clin Immunol Pract
January 2025
Department of Otolaryngology-Head and Neck Surgery, University of Iowa, Iowa City, Iowa.
Background: Otitis media with effusion (OME) is associated with comorbidities such as allergic rhinitis, gastroesophageal reflux disease, asthma, and more. Many of these comorbidities can be caused by type 2 inflammation (T2I). This study aims to determine the risk of undergoing OME surgery in patients with and without T2I disease.
View Article and Find Full Text PDFPatient preferences for treatment of chronic rhinosinusitis with nasal polyps.
Rhinology
December 2024
Department of Head and Neck Surgery and Communication Sciences, Duke University School of Medicine, Durham, NC, USA.
Choosing between revision endoscopic sinus surgery (ESS) versus biologic therapy for recurrent chronic rhinosinusitis with nasal polyposis (CRSwNP) is a complex, multifaceted decision that involves not only clinical and financial factors but also patient preferences. Currently, there are no quantitative studies investigating patient preferences for CRSwNP treatment options. Increased awareness of patient-centered approaches to treatment warrant further investigation.
View Article and Find Full Text PDFParadigms and Perspectives: The Evolving Prostaglandin E Story in Chronic Sinus Disease.
J Allergy Clin Immunol
January 2025
Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Jeff and Penny Vinik Center for Translational Immunology Research, Boston, MA, USA 02115.
Chronic Rhinosinusitis with Nasal Polyps and Biologics: A Call for Better Data Standardisation and Presentation in Clinical Studies.
Ther Clin Risk Manag
January 2025
Department of Otolaryngology Head & Neck Surgery, Monash Health, Melbourne, Australia.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is often severe, debilitating and difficult to treat. Recent randomised control trials (RCTs) of biologics that target key inflammatory pathways have demonstrated clinical efficacy in treating CRSwNP. Such RCTs must facilitate meta-analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!